Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Is the rebound window here? Multiple major cryptocurrencies simultaneously trigger TD9 buy signals

Is the rebound window here? Multiple major cryptocurrencies simultaneously trigger TD9 buy signals

AiCoinAiCoin2026/05/29 02:03
Show original
According to AiCoin data, as of 8 a.m. today, several major cryptocurrencies including BTC, ETH, and XRP simultaneously triggered a red TD9 buy signal on the 8-hour period. The TD Sequential (also known as the DeMark Sequential) was developed by technical analysis expert Tom DeMark, and is mainly used to identify trend exhaustion and potential reversal points. Specifically:
● A TD9 signal below the candlestick usually indicates that after a period of continual market decline, the short-term is gradually entering an oversold stage, and prices may enter a rebound window.
● A TD9 signal above the candlestick means upward momentum is fading, and prices may face a pullback.
The fact that several major cryptocurrencies are simultaneously triggering TD9 signals suggests the market may be approaching an emotional turning point in the short term.
However, it’s important to note that a TD9 signal does not guarantee an immediate reversal; if trading volume is weak or key support levels break, prices could still fall further.
The AiCoin Open Data API now supports TD9 / TD13 indicator signal alerts for all trading pairs, enabling users to create automated monitoring, quantitative alert, and strategy systems: https://www.aicoin.com/zh-Hans/opendata
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53